is there actual evidence for positive results for ginko in mci

Current clinical evidence demonstrates some positive effects of Ginkgo biloba preparations, particularly the standardized EGb 761 extract, in the management of mild cognitive impairment (MCI), though the evidence remains heterogeneous and interpretively cautious.

While UK clinical guidelines do not yet explicitly recommend Ginkgo biloba for MCI management, recent well-conducted meta-analyses and biomarker-informed studies provide biologically plausible and statistically significant evidence of modest cognitive and functional benefits in patients with MCI, especially those with biomarker-confirmed Alzheimer’s pathology or vascular cognitive impairment.

A meta-analysis of randomized placebo-controlled trials of EGb 761 at 240 mg daily in patients with mild to moderate dementia and a history of cerebral infarction showed statistically and clinically meaningful improvements in cognition, activities of daily living, and global clinical status compared to placebo, with good tolerability and no increase in serious adverse events Feng et al. 2025. This suggests potential benefit in vascular-related cognitive impairment, a condition overlapping with MCI.

In Alzheimer’s disease spectrum and biomarker-confirmed MCI populations, Ginkgo biloba’s efficacy is more cautiously optimistic. Several decades of symptomatic and prevention trials have yielded modest but heterogeneous improvements, often constrained by methodological variability and mixed dementia populations Yang & Kwak YT 2026. However, recent biomarker-enriched studies focusing on amyloid PET-positive MCI demonstrate that standardized Ginkgo biloba extracts may preserve cognition and daily functioning, accompanied by favorable changes in plasma biomarkers related to amyloid oligomerization—a mechanism-adjacent measure suggesting possible disease-related biological effects Yang & Kwak YT 2026.

These findings highlight the importance of carefully defining populations biologically, using standardized preparations at adequate doses (typically 240 mg/day), and utilizing clinically relevant endpoints integrating cognition and function over sufficient duration. Observational data also report high adherence and patient-perceived benefits of Ginkgo biloba in chronic cognitive impairment Scholl et al. 2026.

While the current UK dementia guidelines principally focus on established pharmacological treatments, Ginkgo biloba preparations like EGb 761 show promise as adjunctive options for managing MCI, particularly in patients with vascular contributions or biomarker evidence of Alzheimer’s pathology, pending further dedicated clinical trials to confirm efficacy and clarify optimal use Feng et al. 2025 Yang & Kwak YT 2026 NICE NG97.NICE CKS